The Raleigh paper looks at how a fear of needles keeps some people away from peptides, and whether strip formats could change that.
Recap by typeshit. Full story at Raleigh News & Observer.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
The surgeon says that after a 45 lb loss on a GLP-1, getting enough daily protein with a low appetite becomes the harder part.
She says the cause is a calorie surplus: some patients still manage high calorie foods and aren't exercising enough while on the drugs.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
Researchers describe a peptide and GPCR pair that lets a fungus sense when it has entered a host and switch on infection. Basic biology, not GLP-1 or wellness peptides.
The drugs may help with joint and back pain, but doctors quoted by MarketWatch flag specific risks for older patients.
Loading…